Publication: Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib
Loading...
Files
Date
2022-08-01
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
OBJECTIVE We investigated the relationship of baseline sarcopenia with toxicities, treatment response, and survival in patients who had non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation and received erlotinib.METHODS Computed tomography images from PET/CT scans before erlotinib treatment were retrospectively assessed. Skeletal muscle index, calculated as skeletal muscle area at third lumbar vertebra level/square of height, was used to define sarcopenia with < 52.4 cm2/m2 for males and < 38.5 cm2/m2 for females. Cox hazard models were conducted to determine predictors of survival.RESULTS The study included 30 patients, and 11 (36.7%) were sarcopenic. All-grade and Grade 3 toxicities were more frequent in sarcopenic group, although it was statistically insignificant (81.8% vs. 63.2%, p=0.282 for all-grade, and 18.2% vs. 10.5%, p=0.552 for grade 3). Response rates were 63.6% in sarcopenic and 68.4% in non-sarcopenic patients (p=0.789). Median progression-free survival was 7.9 and 9.2 months in sarcopenic and non-sarcopenic cases, respectively (p=0.561). However, median overall survival (OS) of sarcopenic patients was significantly shorter than non-sarcopenic ones (11.8 vs. 30.2 months, p=0.023), and sarcopenia predicted OS independently in multivariate analysis (Hazard ratio=2.63, p=0.029).CONCLUSION Early recognition, treatment, and prevention of sarcopenia may improve long-term survival in EGFRmutant NSCLC patients treated with first-line erlotinib.
Description
Keywords
Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji, Sağlık Bilimleri, Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Health Sciences, ONKOLOJİ, Klinik Tıp, Klinik Tıp (MED), ONCOLOGY, CLINICAL MEDICINE, Clinical Medicine (MED), Epidermal growth factor receptor, erlotinib, non-small cell lung cancer, prognosis, sarcopenia, BODY-MASS INDEX, 1ST-LINE TREATMENT, SOLID TUMORS, OPEN-LABEL, CHEMOTHERAPY, TOXICITY, MULTICENTER, DETERMINANT, PREVALENCE, Epidermal growth factor receptor, erlotinib, non-small cell lung cancer, prognosis, sarcopenia
Citation
DEMİRCAN N. C. , ENGÜR C. Ö. , AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., Yasar A., Celebi A., Alan O., Isik S., ÖZGÜVEN S., et al., "Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib", TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2022